Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eichenhorn, M. S.
Right arrow Articles by Scanlon, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eichenhorn, M. S.
Right arrow Articles by Scanlon, P. D.
(Chest. 2003;124:57-62.)
© 2003 American College of Chest Physicians

Lack of Long-term Adverse Adrenal Effects From Inhaled Triamcinolone*

Lung Health Study II

Michael S. Eichenhorn, MD, FCCP; Robert A. Wise, MD, FCCP; Thelma C. Madhok, PhD; Lynn B. Gerald, PhD, MSPH; William C. Bailey, MD, FCCP; Donald P. Tashkin, MD, FCCP and Paul D. Scanlon, MD; and the Lung Health Study Research Group{dagger}

* From Henry Ford Hospital (Dr. Eichenhorn), Detroit, MI; Johns Hopkins University School of Medicine (Dr. Wise), Baltimore, MD; University of Minnesota (Dr. Madhok), Minneapolis, MN; University of Alabama at Birmingham (Drs. Gerald and Bailey), Birmingham, AL; University of California, Los Angeles (Dr. Tashkin), Los Angeles, CA; and Mayo Clinic (Dr. Scanlon), Rochester, MN. {dagger} A complete list of LHS participants is given in the Appendix.

Correspondence to: John E. Connett, PhD, University of Minnesota, Division of Biostatistics, 2221 University Ave SE, #200 Minneapolis, MN 55414-3080; e-mail: john-c{at}ccbr.umn.edu

Study objectives: Inhaled corticosteroids (ICS) are widely used in the treatment of COPD. One of the potential adverse effects of their use is the development of adrenal suppression. Our study aimed to determine the effects of ICS on adrenal function over 3 years of use in patients with COPD.

Methods: Two hundred twenty-one subjects were recruited from the 1,116 patients already enrolled in Lung Health Study II and were randomized to receive either triamcinolone, 1,200 µg, or placebo daily. Basal cortisol levels and cortisol levels at 30 min and 60 min following cosyntropin injection were measured at study entry and after 1 year and 3 years of participation.

Results: Basal cortisol levels in the placebo group were higher than in those receiving active drug at all time points and rose through the study period. There was no suppression of cortisol levels after cosyntropin stimulation at any study point in any subgroup.

Conclusion: Use of inhaled triamcinolone, 1,200 µg/d, over 3 years does not suppress baseline adrenal function or diminish adrenal responsiveness to cosyntropin stimulation.

Key Words: adrenal function • COPD • inhaled corticosteroids • stimulated cortisol response




This article has been cited by other articles:


Home page
 ChestHome page
D. P. Tashkin, H. E. Murray, M. Skeans, R. P. Murray, and for the Lung Health Study Research Group
Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Results From Lung Health Study II
Chest, October 1, 2004; 126(4): 1123 - 1133.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.